The latest survey from the National Venture Capital Association shows that biotechnology is still on a roll [1]with investors. The association tracked 99 biotech deals in the third quarter which were worth $1.1 billion. Frazier Healthcare Ventures is so pumped about developers it's reserved half of its latest $600 million fund for biotech deals. An ongoing obstacle: A reluctance among VCs to back early-stage ventures. Most worrisome trend: The prospect that a new group of politicos in charge of healthcare legislation [2] in Washington DC will chill the life sciences field with talk of reform.
- read the report [3] from BioWorld on venture capital trends
Related Articles:
Venture capitalists bet big on nanotechnology. Report [1]
Bill could improve funding for small biotechs. Report [2]
Biotech sees big money from corporate players. Report [4]
The Top 5 VC deals of the first half of 2007. Report [5]
Links:
[1] http://www.fiercebiotech.com/story/venture-capitalists-bet-big-nanotechnology/2007-09-12
[2] http://www.fiercebiotech.com/story/bill-could-improve-funding-for-small-biotechs/2007-10-05
[3] http://www.bioworld.com/servlet/com.accumedia.web.Dispatcher?next=bioWorldHeadlines_article&forceid=46278
[4] http://www.fiercebiotech.com/story/biotech-sees-big-money-corporate-players/2007-09-06
[5] http://www.fiercebiotech.com/special-reports/top-5-financing-deals-first-half-2007